Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (CSE: $TER.C) (CSE: $TTT.C), (TSX: $VFF.TO) (NASDAQ: $VFF), (TSX: $ALEF.TO), (TSXV: $EMH.V) (OTC: $HEMP), (TSXV: $ENW.V)
Delta, Kelowna, BC –October 7, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts
In today’s podcast we look at a few early announcements.
But first, RYAH Medtech, Inc., a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry, released a data analytics report on chronic pain and cannabis. The data, taken from RYAH’s proprietary data pool, and related insights, examine medical cannabis pain patient demographics and how different types of chronic pain respond to different strains of medical cannabis.
"Pain is a top concern for medical cannabis patients visiting physicians and dispensaries and we hope that this report will help inform the public on how some patients are personalizing their cannabis treatments to achieve better outcomes. As a company rooted in big data and predictive analysis, RYAH is uniquely positioned to use our artificial intelligence platform to provide insights on the complete medical plant life cycle from seed to consumption,” said Gregory Wagner, Chief Executive Officer of RYAH.
The report found that pain is the 4th most popular reason medical cannabis patients seek treatment, with slightly more men than women treating their pain with cannabis. Both groups of patients experienced comorbidities including anxiety, depression, stress, insomnia and mood swings.
In terms of strain preference, patients rated Indica and Indica dominant hybrids as providing the most symptom relief. Examples of some of these Indica dominant strains include Blueberry Diesel, Mango, and LA Confidential. Patients also preferred strains with percentages of THC above 15%, considered to be a relatively high concentration of THC. One of the more unexpected findings was that CBD content did not seem to play a major role in terms of symptom relief.
The full report can be read here.
TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) today announced that it has received approval from Health Canada for significant expansion at its facility in Mississauga, Ontario. This approval increases licensed space at the Mississauga facility nearly three-fold from 17,800 sq. ft. to 51,800 sq. ft., and includes additional cultivation capacity, a commercial kitchen, formulation rooms and increased primary and secondary packaging capacity to allow for new product formats and extracts for the Canadian Cannabis 2.0 market.
"Achieving this approval milestone is a crucial step in our plan to cultivate premium grade cannabis at scale for distribution to the EU and other international markets," said Michael Nashat, CEO of TerrAscend. "In addition, our newly licensed processing operations pave the way for TerrAscend to meet the significant increased consumer demand expected upon the launch of Cannabis 2.0. Over the coming months, we plan on introducing the Canadian market to the proven brands and formulations from our US operations, as well as new proprietary dosage forms developed in our EU GMP certified Ontario-based facility."
First licensed for cultivation in July 2017, TerrAscend's 67,300 sq. ft. GMP certified indoor cannabis facility located in Mississauga, Ontario, is focused on serving the Canadian medical and adult-use markets, conducting research & development for plant sciences and formulations, and serving as a platform for export of cannabis products to Europe and other international jurisdictions.
TruTrace Technologies Inc. (CSE: TTT) (OTCQB: TTTSF) and Sigma Analytical Services, a provider of comprehensive testing and analytical services for the cannabis industry, today announced that the two companies have entered into a letter of intent to establish a strategic working relationship.
Pursuant to the LOI, TruTrace plans to include Sigma Analytical as a genetics verification and testing partner in its blockchain-secured traceability ecosystem, and the parties will explore development and integration opportunities to rapidly expedite and optimize testing processes in the cannabis and hemp industries.
Sigma Analytical is also expected to participate in the TruTrace Technologies and Shoppers Drug Mart medical cannabis verification pilot program as a testing partner. The Pilot Program, which is designed to increase transparency, interoperability and product identification within the medical cannabis industry, uses TruTrace's StrainSecure™ technology as a central hub for identity management, asset tracking, validation, and product authentication.
"Sigma has been advancing the understanding of cannabis chemistry and has established a global scientific network of pioneers to facilitate standardizing testing and quality assurance in this new and promising field of science," said Ashton Abrahams, Chief Operating Officer of Sigma Analytical. "Working with TruTrace and Shoppers Drug Mart to track and trace the process and products will have significant synergy with what Sigma is doing and will be valuable to the fast-growing cannabis industry."
"We are pleased to add Sigma Analytical as a partner in our StrainSecure ecosystem," said TruTrace Technologies CEO Robert Galarza. "The Sigma team has established a track record of innovation in the cannabis industry and we look forward to collaborating with them as we continue to build out our platform and processes."
As a full-service testing and research GMP-compliant laboratory, Sigma Analytical offers comprehensive testing and analytical services, as well as R&D, and consulting in cannabis, hemp and derived products across North and South America. Equipped with the most advanced analytical instruments and validated SOPs, Sigma possesses a tremendous amount of acquired know-how and expertise in the areas of cannabis and hemp sample preparation, processing, digestion, method development, and analysis.
Under the StrainSecure™ program, the TruTrace team collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the program.
Listen to our previous interview with Robert Galarza, CEO of TruTrace here.
Village Farms International, Inc. (TSX: VFF) (NASDAQ: VFF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried cannabis products to the British Columbia Liquor Distribution Branch, which acts as the provincial wholesaler of non-medical cannabis, supplying licensed private retailers and the government-run online store and stand-alone BC Cannabis Stores. Pure Sunfarms expects its first products to soon be available to retail customers in British Columbia.
Pure Sunfarms began shipping product to the Ontario provincial wholesaler, the Ontario Cannabis Retail Corporation (the "OCRC", operating as the Ontario Cannabis Store), in September. Combined, Ontario and British Columbia comprise more than half of Canada's population.
"It's a testament to Pure Sunfarms' product quality, reputation and team, that in less than four weeks following the long-awaited receipt of its license amendment to sell directly to provincial wholesalers on September 6, it is now shipping its proudly BC-grown product to its second provincial customer, adding its home province of British Columbia to Canada's largest province, Ontario, where its products are already available," said Michael DeGiglio, CEO, Village Farms.
Pure Sunfarms continues to advance discussions with other provincial distributors for potential supply agreements to further expand its presence in the Canadian cannabis market.
Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) announced completing the construction of its Paris Processing facility’s Phase II expansion and secured full site occupancy on October 4, 2019, following the successful completion of County of Brant inspections. The Paris Phase II expansion is a 30,000 sq. ft. facility entirely dedicated to the extraction, production, packaging and distribution of high-margin, value-added cannabis health and wellness products.
The expansion builds upon the current, licensed and operational Paris facility, which features cultivation rooms and handles all extraction, packaging and order fulfillment for Aleafia Health’s medical, adult-use and international sales.
Paris will feature an initial 115,000 kg dried flower equivalent extraction capacity, a 2,775 per cent increase over the Company’s current 4,000 kg DFE extraction capacity. The Company expects that Paris can through-put all dried flower grown by Aleafia Health, including at its newly expanded, 86-acre Port Perry Outdoor Grow site.
To complete the final stage of securing its required Licence Amendment, the Company’s wholly-owned subsidiary, Emblem Cannabis Corp., expects to submit its final evidence package to Health Canada this October, demonstrating the facility’s operational readiness.
The facility is purpose-built to meet European Union Good Manufacturing Practices certification requirements. EU-GMP certified facilities demonstrate the highest level of pharmaceutical-grade quality, and securing the certification will allow Aleafia Health to begin exporting finished goods including cannabis oils and capsules to the EU.
Through the Aleafia Health Germany joint-venture with German pharmaceutical wholesaler and logistics company Acnos Pharma GmbH, Aleafia will gain access to the burgeoning German medical cannabis market, with access to 22,000 pharmacies and 110 distribution centres.
The Paris expansion will rapidly accelerate Aleafia Health’s production capacity, and ability to create a wide variety of differentiated products across multiple categories. It has been built specifically to allow for further, significant expansions of extraction capacity by utilizing additional machinery. For instance, the existing capital expenditures budget accounts for additional ethanol extraction machinery that would bring total capacity to 190,000 kg DFE and would take approximately eight weeks to bring online.
“The Paris expansion represents the crown jewel of Aleafia Health’s cannabis ecosystem. This facility will allow us to rapidly expand the production of high-margin derivative products, while adding new, differentiated formats that are grown, processed, packaged and exported by Aleafia Health,” said CEO Geoffrey Benic. “We look forward to bringing the next generation of cannabis products to market, while greatly expanding our international footprint in Germany, Australia and beyond.”
Emerald Health Therapeutics’ (TSXV: EMH) (OTCQX: EMHTF) wholly-owned cannabis production facility, Verdélite, in St. Eustache, Quebec, has received from Health Canada a license amendment for the complete growing and processing area in its 88,000 square foot indoor facility. The additional 50,000 square feet will allow Verdélite to expand production from 4 to 21 highly-controlled-environment grow rooms and to a total of 16 processing rooms. Planting in the newly licensed area is starting immediately, with the plan focused on having the expanded facility fully planted in eight weeks.
“Verdélite is now fully built and licensed across all its growing and processing areas, and I congratulate the team for this accomplishment,” said Thierry Schmidt, President of Verdélite. “As we expand production of Emerald Health Therapeutics products sold under the Emerald sales license, this step enables us to also continue advancing our marketing strategy encompassing Verdélite brands and direct sales to provincial/territorial wholesalers and authorized Canadian private retailers.”
“This new license amendment allows Verdélite to transition into its full commercial phase and positions Verdélite as a key growth contributor to Emerald's financial results in 2020,” said Riaz Bandali, Chief Executive Officer of Emerald. “With this extended, controlled indoor growing space and Verdélite’s unique cannabis strains, we aim to bring distinct and unique consumer-driven products to the Quebec market.”
Verdélite is a vertically integrated seed-to-sale indoor operation optimized for year-round production of high-quality craft cannabis through its highly controlled environment. Its established packaging and processing line are well equipped to manage significant volume and a wide diversity of value-added products.
Hemp, Inc. (OTC: HEMP), was recently featured in the renowned international news outlet, United Press International (UPI), discussing the hemp industry and how Hemp, Inc. is utilizing the crop beyond cannabidiol (CBD).
The UPI article titled, “Hemp hardwoods, bioplastics expand crop use beyond CBD” discusses the current state of the hemp industry and expectations for the future. The article promptly dives into the changing industry and the revised route some farmers are taking to meet the growing demand to fully utilize the newly legal crop's full potential.
The article discussed the sprouting of businesses within various sectors of the hemp industry such as hemp-based hardwood and bioplastics. The hemp bioplastics industry is one Hemp, Inc. recently announced its entry into, marking it the Company’s third venture into the natural product’s market.
The article states, “The firm is milling a powdery bioplastic stock from hemp and kenaf -- another natural-fiber plant. For now, the company imports from Europe hemp hurd, a byproduct of hemp processing, and grinds it with kenaf.”
In an interview with UPI, Hemp, Inc. CEO Bruce Perlowin discussed his excitement upon entering this sector of the hemp industry, "I'm in heaven that we're part of the supply chain to make bioplastic. I've been an environmentalist and eco-commando since I was in high school."
Additionally, the article highlights the Company’s operations in both North Carolina, where the hemp bioplastics material is processed and the operations in Oregon, where the company’s processing facility extracts CBD oil.
An excerpt from the article states, “Before bioplastics companies can grow and experiment with hemp-based products, a pathway has to be built from the plant to the plastic, Perlowin said. There are too few hemp processing facilities to generate the raw materials needed by plastic companies, he said.”
Perlowin is quoted at the end of the UPI article explaining that Hemp, Inc. has one machine at the North Carolina processing facility for hemp bioplastics, but states there should be 200 others across the country to help fill the demand.
EnWave Corporation (TSX-V:ENW) today announced that NutraDried Food Company LLC, a wholly-owned subsidiary of EnWave, will install a third large-scale 120kW Radiant Energy Vacuum (“REV™”) machine to expand production capacity for its rapidly growing Moon Cheese® snack product line.
Moon Cheese® is currently sold in over 25,000 points of distribution in North America including premier retailers such as Starbucks, Costco, Whole Foods, Publix, Target, and Wegmans. The brand has also recently gained distribution at HEB, ShopRite, Sprouts, and Raley’s. Moon Cheese is in the midst of a major brand re-launch reflecting world-class new packaging, new varieties (Garlickin’ Parmesan and Cheddar Bacon Me Crazy), and new sizes. The re-launch has been enthusiastically received by retail partners and will be supported by significant investments in sales and marketing. NutraDried revenue has more than doubled in each of the past two years and aggressive growth rates are expected to continue.
EnWave’s Board of Directors has approved a capital investment budget of up to CA $8.0 MM for the Company to construct a new 120kW nutraREV® machine and to outfit the NutraDried manufacturing facility to allow for robust commercial growth. The capital expansion will include upgrades to improve productivity and will allow for the potential installation of two more nutraREV® processing lines. This investment in the purpose-built commercial infrastructure today will allow for up to a total of five nutraREV® machines to be commissioned to address commercial growth. At the completion of the initial expansion
NutraDried will have three large-scale nutraREV® machines in commercial production.
With over $20 million of cash on hand, EnWave has ample capital available to support and optimize the investment. The increased manufacturing capacity will enable continued distribution and velocity growth of the Moon Cheese® brand.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
